Lilotomab
Lilotomab is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Nordic Nanovector.
Mechanism of action[edit | edit source]
Lilotomab works by binding to the CD37 antigen, a protein that is abundantly expressed on the surface of B cells. By binding to this antigen, lilotomab can deliver a dose of radiation directly to the cancer cells, killing them and reducing the size of the tumor.
Clinical trials[edit | edit source]
Lilotomab has been tested in several clinical trials for the treatment of Non-Hodgkin lymphoma. In these trials, lilotomab was used in combination with Betalutin, a radioimmunotherapeutic agent also developed by Nordic Nanovector.
Side effects[edit | edit source]
Like all drugs, lilotomab can cause side effects. The most common side effects reported in clinical trials include nausea, fatigue, and anemia. Less common side effects include neutropenia, thrombocytopenia, and lymphopenia.
See also[edit | edit source]
References[edit | edit source]
Lilotomab Resources | ||
---|---|---|
|
|
|
Find a healthcare provider anywhere in the world quickly and easily!
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
WikiMD is the world's largest, free medical and wellness encyclopedia edited only by professionals. Advertise!
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD